SEC Form 4 · accession 0001106578-26-000143
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairperson & CEO · Director
Period of report
Sep 16, 2026
Accepted (ET)
Sep 17, 2026 · 4:43 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 16, 2026 | M | 9,500 | $117.76 | A | 333,943 | I | by Trust |
| Common StockF3,F2 | Sep 16, 2026 | S | 2,080 | $498.4505 | D | 331,863 | I | by Trust |
| Common StockF4,F2 | Sep 16, 2026 | S | 1,220 | $499.1528 | D | 330,643 | I | by Trust |
| Common StockF5,F2 | Sep 16, 2026 | S | 492 | $500.1945 | D | 330,151 | I | by Trust |
| Common StockF6,F2 | Sep 16, 2026 | S | 708 | $501.5206 | D | 329,443 | I | by Trust |
| Common StockF7,F2 | Sep 16, 2026 | S | 2,160 | $502.4406 | D | 327,283 | I | by Trust |
| Common StockF8,F2 | Sep 16, 2026 | S | 1,538 | $503.5299 | D | 325,745 | I | by Trust |
| Common StockF9,F2 | Sep 16, 2026 | S | 1,182 | $504.1724 | D | 324,563 | I | by Trust |
| Common StockF10,F2 | Sep 16, 2026 | S | 120 | $505.20 | D | 324,443 | I | by Trust |
| Common Stock | holding | — | — | — | 40,513 | D | ||
| Common Stock | holding | — | — | — | 166 | I | by Spouse | |
| Common StockF11 | holding | — | — | — | 249,108 | I | by Trust | |
| Common StockF12 | holding | — | — | — | 45,596 | I | by Trust | |
| Common StockF13 | holding | — | — | — | 8,902 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF15,F14 | $117.76 | Sep 16, 2026 | M | 9,500 | D | — | Mar 15, 2027 | Common Stock | 9,500 | 423,410 | I |
Explanation of responses
- F1This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10This transaction was executed in multiple trades at prices ranging from $505.08 to $505.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F12Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F13Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F14These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
- F15Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3This transaction was executed in multiple trades at prices ranging from $497.69 to $498.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $498.71 to $499.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $499.95 to $500.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $500.95 to $501.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $501.97 to $502.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8This transaction was executed in multiple trades at prices ranging from $502.97 to $503.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9This transaction was executed in multiple trades at prices ranging from $503.97 to $504.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.